Navigation Links
Rodobo International, Inc. Reports Q2 and First Half of 2009
Date:5/18/2009

HARBIN, China, May 18 /PRNewswire-Asia-FirstCall/ -- Rodobo International, Inc. (OTC Bulletin Board: RDBO), one of the leading independent dairy companies in China, reported financial results for the second quarter and first six months ended March 31, 2009.

Second quarter financial highlights include:

Revenue for the second quarter ended March 31, 2009 was $6.3 million, an increase of 19% compared to Q2 2008. This increase was primarily driven by volume growth, with average selling price remaining flat over both periods. The new product series "Healthy Elderly", launched in October 2008, attributed approximately $1.1 million to the second quarter.

Sales of Whole Milk Powder Formula represented 39% of total sales in Q2 2009 compared to 27% in Q2 2008. Sales of Baby/Infant Formula represented 44% of total sales in Q2 2009 compared to 61% in Q2 2008. Sales of Adult Formula represented 17% of total sales in Q2 2009 compared to 12% in Q2 2008.

Gross profit for Q2 2009 was $2.3 million, down 4% compared to Q2 2008. The overall gross margin decreased from 45% in Q2 2008 to 36% in Q2 2009. The increase in the costs of goods sold and the decrease in gross margin was mainly driven by a different product mix that included more sales of lower margin products. Additionally, gross margin for Whole Milk Powder Formula decreased in 2009 compared to 2008 due to a 24% increase in the cost of raw milk.

Operating income in the first three months ended March 31, 2009 was $0.74 million, decrease of 34% compared to the same period last year. The decrease is mainly attributed to higher depreciation expenses due to equipment purchase and advertising expenses to support the growth.

Net income was $1.2 million relatively flat compared to Q2 2008.

Six months financial highlights include:

Revenue for the first half ended March 31, 2009 was $15.2 milli
'/>"/>

SOURCE Rodobo International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
6. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
7. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
8. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
9. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... announces that a new market research report ... Neurostimulation - A Global Market Perspective ... world neurostimulation market stands enthused by the ... resultant rise in age-related diseases such as, ...
(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...
(Date:12/2/2009)... December 2 Gamida Cell announced today,a feasibility ... of a gene therapy product which combines technology ... product may have potential to,treat inherited anemias such ... Gamida Cell is developing a series of technologies ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...
... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2
... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...
... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...
... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...
Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2
... sizes available for use with 96- or 384-well PCR ... for ease of location on 96-tube plates End ... skirt of the plate* Efficient sealing is achieved ... conjunction with screw or clip-down hot lid thermal cyclers ...
... as a wash buffer for Michels Transport Fluid ... for transportation of specimens (such as renal biopsies ... may remain in Transport Fluid for up to ... Fluid is not a fixative and is not ...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
Biology Products: